Table 4.
Differences in bone metabolic profiles and renal function between PHPT patients and controls.
| Patients Before MWA | Patients after MWA a | The control group | |
|---|---|---|---|
| 25(OH)D (ng/mL) | 13.1 (10.2, 17.8)* | 18.5 (15.6, 21.6)△△ | 17.7 (15.25, 25.15) |
| ALP (U/L) | 89 (73, 167)** | 72 (51, 100)△△ | 61 (49, 73) |
| Osteocalcin (ng/mL) | 35 (21, 61)*** | 22 (14, 36)*△△ | 13 (10, 15) |
| Total P1PN (ng/mL) | 89.46 (64.57, 158.60)** | 61.85 (32.40, 89.37)△△ | 48.87 (27.96, 50.51) |
| β-CTX(pg/mL) | 1099.00 (731.90, 1391.00)*** | 372.30 (197.15, 498.15)△△ | 310.60 (167.65, 447.05) |
| Creatinine (μmol/L) | 67 (60, 74)* | 69 (59, 75)* | 54 (52, 67) |
| eGFR (mL/min/1.73 m2) | 89.6 (76.5, 106.7)** | 94.3 (74.6, 109.2)* | 119.14 (103.07, 129.44) |
MWA, microwave ablation; PHPT, primary hyperparathyroidism; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; ALP, alkaline phosphatase; P1PN, procollagen type 1 N-telopeptide; β-CTX, C-terminal telopeptide of β-I collagen; eGFR, estimated glomerular filtration rate.
Compared with the control group, *P<0.05, **P<0.01, ***P<0.001; Compared with patients before MWA, △△P < 0.01.
The last follow-up results were listed in patients after MWA.
Serum 25(OH)D level <20 ng/mL, <12 ng/mL, between 20~30 ng/mL and ≥30 ng/mL are considered as vitamin D insufficiency, deficiency, moderate and sufficiency respectively.
Normal reference ranges: ALP 35~100 U/L. Osteocalcin 11~43 ng/mL women before menopause, 15~46 ng/mL women post menopause; 24~70 ng/mL, 14~42 ng/mL and 14~46 ng/mL for man between 18~30 years old, 30~50 years old and 50~70 years old, respectively; 13~48 ng/mL for patients with osteoporosis. P1NP 15.13~58.59 ng/mL, 16.27~73.87 ng/mL and 9.06~76.24 ng/mL for premenopausal women, postmenopausal women and men, respectively. β-CTX 25.00~573.00 pg/mL, 104.00~1008.00 pg/mL and 16.00~584.00 pg/mL for premenopausal women, postmenopausal women and men, respectively; Creatinine: 45~84 μmol/L; eGFR was calculated using Chinese modified modification of diet in renal disease (MDRD) study equation, eGFR(mL/min/1.73 m2)=186×creatinine-1.154×age-0.203×0.742 (female). The renal dysfunction was defined as eGFR<60 mL/min/1.73m2.
The intra-assay variation: PTH 2.1%; ALP 2.2%; 25(OH)D 6.7%; osteocalcin 1.3%; P1PN 1.7%; β-CTX 1.5%.
The inter-assay variations: PTH 1.4-1.7%; ALP 0.6-0.7%; 25(OH)D 2.7-4.6%; osteocalcin 0.9-1.3%; P1PN 1.2-1.6%; β-CTX 1.4-1.6%.